{
    "Question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive MTX monotherapy or an alternative csDMARD monotherapy?",
    "Comparison": {
        "MTX monotherapy versus SSZ. ": {
            "filename": "PICO 2a_Comparison 2.json",
            "Explanations": {
                "a": "Downgraded by one level due to serious risk of bias. Lack of allocation and lack of blinding of outcome assessors of non-radiographic outcomes in the study with the higher weight",
                "b": "I2= 41%",
                "c": "Downgraded by one level due to serious imprecision. Small sample size.",
                "d": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Very small sample size.",
                "e": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size and low number of events.",
                "f": "I2= 44% ",
                "g": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect. Small sample size."
            }
        },
        " MTX monotherapy versus LEF. ": {
            "filename": "PICO 2a_Comparison 3.json",
            "Explanations": {
                "a": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding of patients, personnel, and outcome assessors."
            }
        },
        " SSZ versus HCQ ": {
            "filename": "PICO 2a_Comparison 4.json",
            "Explanations": {
                "a": " Downgraded by one level due to serious risk of bias. Lack of allocation concealment. ",
                "b": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting harm and values suggesting benefit. Small sample size. "
            }
        }
    },
    "References": {
        "1": "Dougados M. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases. 1999;58(4):220.",
        "2": "Haagsma C, van Riel P, de Jong A, van de Putte L. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology. 1997;36(10):1082.",
        "3": "Zeb S. Comparison of short-term efficacy of leflunomide and methotrexate in active rheumatoid arthritis. Journal of Postgraduate Medical Institute. 2016;30(2):177.",
        "4": "Nuver Zwart IH, van Riel PL, van de Putte LB, Gribnau FW. A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine. Annals of the Rheumatic Diseases. 1989;48(5):389.",
        "5": "Choi H, Seeger J, Kuntz K. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. Journal of Rheumatology. 2002;29(6):1156."
    }
}